Navigation Links
Sosei Signs Definitive Distribution Agreement With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Date:11/2/2009

TOKYO, November 2 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a definitive distribution agreement with ASKA Pharmaceuticals Co., Ltd. ("ASKA", TSE First Section Index: 4514) for the commercialisation of the emergency contraceptive pill SOH-075 (NorLevo(R)).

NorLevo(R) is an oral emergency contraceptive "morning after pill" which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo(R) contains only levonorgestrel as an active ingredient. The dosing is started within 72 hours after unprotected sexual intercourse. NorLevo(R) was first launched in Europe in 1999 and is currently approved in some 60 countries, the product being both safe and effective as an oral emergency contraceptive for post-coital use.

Sosei have acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The NDA application for SOH-075 was submitted in Japan in September 2009.

The agreement is based on the terms of a binding letter of agreement that was announced on 22 October 2008. According to this agreement, Sosei is responsible for development and registration and ASKA for sales and marketing.

In accordance with the agreement, Sosei will receive upfront, milestone payments as well as a margin on product sales to ASKA.

Notes for Editors:

About Sosei

Sosei is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan. For further information about Sosei, please visit http://www.sosei.com.

SOURCE Sosei Group Corporation


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
5. Sosei Assigns AD 923 Assets to Pharmasol
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
11. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... , August 17, 2017 DarioHealth ... Company with mobile health and big data solutions, ... agreements with domestic and non-U.S. investors for the ... and shares of the Company,s newly designated Series ... offerings. The Company expects to conduct a closing ...
(Date:8/15/2017)... HIGH POINT, N.C. , Aug. 15, 2017  Axium Pharmaceuticals Inc., ... epilepsy is rumored to be in the beginning stages of an IPO. ... billion annually on epilepsy medications with the average cost of a prescription ... ... Another staggering figure is ...
(Date:8/11/2017)... 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it will release its ... host a conference call at 9:00am ET. The Company ... results and its strategy and outlook for the remainder ... Erez Raphael , Chief Executive Officer, and Zvi ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... 22, 2017 , ... “To Walk Away”: a captivating and romantic sequel ... Koontz. “To Walk Away” is the creation of published author, Larry R. Sherman, a ... manuscripts in chemistry and religion, as well as four novels. , Though the ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: Walid’s spiritual journey ... author, Julianne Hale, a consultant for the Intelligence Community. For more than ... the Near East region. Julianne has written hundreds of reports for the ...
(Date:8/22/2017)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, a ... of modern life continually makes more demands on time and energy, people are finding ... people in vicious high/low cycles and can also cause long term health issues. More ...
(Date:8/21/2017)... (PRWEB) , ... August 22, 2017 , ... PracticeMatch, a ... to help healthcare employers connect with physicians and advanced practitioners like nurse practitioners ... career fairs in August through November of this year. The online career fairs ...
(Date:8/21/2017)... Angeles, California (PRWEB) , ... August 21, 2017 ... ... is announcing the addition of two plastic surgery fellows for academic year 2017-2018, ... designed for candidates who have successfully completed residency in Plastic and Reconstructive Surgery. ...
Breaking Medicine News(10 mins):